ArticleResearch square2026

Elevated DYRK1A in Primary Tauopathies and Therapeutic Targeting with the Brain-Penetrant Inhibitor DYR533.

Ramon Velazquez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.